Ascendis Pharma (NASDAQ: ASND) reported Q1 EPS of ($0.87), $0.14 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $416 thousand versus the consensus estimate of $1.37 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.